Monopar Therapeutics Inc. announced its fourth quarter and full-year 2025 financial results, reporting a net loss of $5.2 million for Q4 2025 and $13.7 million for the full year, and provided a business update including plans to submit an NDA for ALXN1840 in mid-2026. The company ended 2025 with $140.4 million in cash and expects its funds to support operations through at least December 31, 2027.
Key takeaways
Net loss for Q4 2025 was $5.2 million ($0.61 per share), compared to $10.9 million ($2.23 per share) for Q4 2024.
Net loss for full-year 2025 was $13.7 million ($1.85 per share), compared to $15.6 million ($4.11 per share) for full-year 2024.
Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million, with funds expected to support operations through at least December 31, 2027.
Monopar plans to submit a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in mid-2026.
R&D expenses for Q4 2025 were $3.9 million, down from $9.9 million in Q4 2024, primarily due to the absence of one-time ALXN1840 in-licensing expenses.
G&A expenses for Q4 2025 were $2.2 million, up from $1.2 million in Q4 2024, primarily due to higher personnel and patent legal fees.